Chromosomal Defects and Survival in Patients with Adult T-cell Leukemia/lymphoma After Allogeneic HSCT

Overview

Journal Blood Adv

Specialty Hematology

Date 2021 Jan 26

PMID 33496743

Citations 1

Authors

Nobuaki Nakano

Atae Utsunomiya

Keitaro Matsuo

Noriaki Yoshida

Masao Seto

Kouichi Ohshima

Hiroshi Fujiwara

Shigeo Fuji

Yoshifusa Takatsuka

Ayumu Ito

Toshihiro Miyamoto

Youko Suehiro

Hirohisa Nakamae

Yasushi Sawayama

Mitsuhiro Yuasa

Yasuhiko Miyazaki

Shuichi Ota

Kazunori Imada

Takahiro Fukuda

Tatsuo Ichinohe

Yoshiko Atsuta

Koji Kato

Affiliations

Soon will be listed here.

Abstract

Adult T-cell leukemia/lymphoma (ATL) cells frequently exhibit chromosomal abnormalities, including numerical aberrations and structural defects. However, no studies have examined the correlation between these abnormalities and survival in patients with ATL after allogeneic HSCT (allo-HSCT). In this study, 300 patients with ATL (median age, 55 years; range, 24-74) who were registered in a Japanese nationwide registry database were analyzed. The majority (n = 183) had acute ATL. Specimens for chromosomal analysis were collected from bone marrow (n = 166), lymph nodes (n = 86), peripheral blood (n = 41), and other locations (n = 7). In survival analyses, breakpoints at 2q (hazard ratio [HR], 1.63; 95% confidence interval [CI], 1.12-2.38; P = .012) and 5q (HR, 2.18; 95% CI, 1.25-3.80; P = .006) were significantly poor prognostic factors for overall survival (OS). In terms of ATL-related death, loss of chromosome 14 and breakpoints at 3p, 1q, 5q, and 6q were extracted as significantly poor prognostic factors. Moreover, complex karyotypes were associated with ATL-related death. This study of the survival impact of chromosomal abnormalities in patients with ATL after allo-HSCT demonstrated that several structural breakpoints were independent risk factors for OS and ATL-related death.

Citing Articles

Outcomes in human T-cell leukemia virus type I carriers after hematopoietic stem cell transplantation for diseases other than adult T cell leukemia/lymphoma: a Japanese national survey.

Nakano N, Nakasone H, Fuji S, Shinohara A, Suzuki R, Utsunomiya A Lancet Reg Health West Pac. 2023; 40:100902.

PMID: 38106528 PMC: 10721504. DOI: 10.1016/j.lanwpc.2023.100902.

References

Ishida T, Fujiwara H, Nosaka K, Taira N, Abe Y, Imaizumi Y . Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002. J Clin Oncol. 2016; 34(34):4086-4093. DOI: 10.1200/JCO.2016.67.7732. View

Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y . VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007; 25(34):5458-64. DOI: 10.1200/JCO.2007.11.9958. View

Bazarbachi A, Plumelle Y, Ramos J, Tortevoye P, Otrock Z, Taylor G . Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol. 2010; 28(27):4177-83. DOI: 10.1200/JCO.2010.28.0669. View

Ratner L, Waldmann T, Janakiram M, Brammer J . Rapid Progression of Adult T-Cell Leukemia-Lymphoma after PD-1 Inhibitor Therapy. N Engl J Med. 2018; 378(20):1947-1948. DOI: 10.1056/NEJMc1803181. View

Yoshimitsu M, Tanosaki R, Kato K, Ishida T, Choi I, Takatsuka Y . Risk Assessment in Adult T Cell Leukemia/Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2017; 24(4):832-839. DOI: 10.1016/j.bbmt.2017.11.005. View

Choi I, Wake A, Uike N, Taniguchi S, Moriuchi Y, Miyazaki Y . Treatment of patients with adult T cell leukemia/lymphoma with cord blood transplantation: a Japanese nationwide retrospective survey. Biol Blood Marrow Transplant. 2014; 20(12):1968-74. DOI: 10.1016/j.bbmt.2014.08.012. View

Kamada N, Sakurai M, Miyamoto K, Sanada I, Sadamori N, Fukuhara S . Chromosome abnormalities in adult T-cell leukemia/lymphoma: a karyotype review committee report. Cancer Res. 1992; 52(6):1481-93. View

Kanda Y . Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2012; 48(3):452-8. PMC: 3590441. DOI: 10.1038/bmt.2012.244. View

Fuji S, Yamaguchi T, Inoue Y, Utsunomiya A, Moriuchi Y, Uchimaru K . Development of a modified prognostic index for patients with aggressive adult T-cell leukemia-lymphoma aged 70 years or younger: possible risk-adapted management strategies including allogeneic transplantation. Haematologica. 2017; 102(7):1258-1265. PMC: 5566038. DOI: 10.3324/haematol.2017.164996. View

10.

Kronke J, Fink E, Hollenbach P, MacBeth K, Hurst S, Udeshi N . Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Nature. 2015; 523(7559):183-188. PMC: 4853910. DOI: 10.1038/nature14610. View

11.

Satake M, Yamaguchi K, Tadokoro K . Current prevalence of HTLV-1 in Japan as determined by screening of blood donors. J Med Virol. 2011; 84(2):327-35. DOI: 10.1002/jmv.23181. View

12.

Katsuya H, Yamanaka T, Ishitsuka K, Utsunomiya A, Sasaki H, Hanada S . Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma. J Clin Oncol. 2012; 30(14):1635-40. DOI: 10.1200/JCO.2011.38.2101. View

13.

Kataoka K, Nagata Y, Kitanaka A, Shiraishi Y, Shimamura T, Yasunaga J . Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet. 2015; 47(11):1304-15. DOI: 10.1038/ng.3415. View

14.

Blazar B, Taylor P, Boyer M, Panoskaltsis-Mortari A, Allison J, Vallera D . CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells. J Immunol. 1997; 159(7):3460-73. View

15.

Hishizawa M, Kanda J, Utsunomiya A, Taniguchi S, Eto T, Moriuchi Y . Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood. 2010; 116(8):1369-76. DOI: 10.1182/blood-2009-10-247510. View

16.

Shimoyama M . Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991; 79(3):428-37. DOI: 10.1111/j.1365-2141.1991.tb08051.x. View

17.

Bazarbachi A, Cwynarski K, Boumendil A, Finel H, Fields P, Raj K . Outcome of patients with HTLV-1-associated adult T-cell leukemia/lymphoma after SCT: a retrospective study by the EBMT LWP. Bone Marrow Transplant. 2014; 49(10):1266-8. DOI: 10.1038/bmt.2014.143. View

18.

Ishida T, Hishizawa M, Tanosaki R, Fukuda T, Taniguchi S, Eto T . Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study. Blood. 2012; 120(8):1734-41. DOI: 10.1182/blood-2012-03-414490. View

19.

Fukushima T, Nomura S, Shimoyama M, Shibata T, Imaizumi Y, Moriuchi Y . Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma (JCOG0902A). Br J Haematol. 2014; 166(5):739-48. DOI: 10.1111/bjh.12962. View

20.

Itoyama T, Chaganti R, Yamada Y, Tsukasaki K, Atogami S, Nakamura H . Cytogenetic analysis and clinical significance in adult T-cell leukemia/lymphoma: a study of 50 cases from the human T-cell leukemia virus type-1 endemic area, Nagasaki. Blood. 2001; 97(11):3612-20. DOI: 10.1182/blood.v97.11.3612. View